Cipher PharmaceuticalsCPHRF +1.94%96 ROC (Joel Greenblatt) % is 3,820.44% as of Mar. 2026, which is 581% above its 10-year median of 560.86. GuruFocus rates CPHRF with a GF Scoreâ„¢ of 96/100 and a GF Valueâ„¢ of $12.21 (Fairly Valued). The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 99.69% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cipher Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3,820.44%.
The historical rank and industry rank for Cipher Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
CPHRF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 184.23 Med: 560.86 Max: 2189.79
Current: 1861.06
During the past 13 years, Cipher Pharmaceuticals's highest ROC (Joel Greenblatt) % was 2189.79%. The lowest was 184.23%. And the median was 560.86%.
CPHRF's ROC (Joel Greenblatt) % is ranked better than 99.69% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs CPHRF: 1861.06
Cipher Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 19.10% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Cipher Pharmaceuticals ROC (Joel Greenblatt) % Related Terms
Cipher Pharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cipher Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPHRF vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipher Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cipher Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 3,820.44% mean?
Cipher Pharmaceuticals (CPHRF) has a ROC (Joel Greenblatt) % of 3,820.44% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cipher Pharmaceuticals and its competitors. This is 581% above median its historical median of 560.86. Over the past decade, Cipher Pharmaceuticals' ROC (Joel Greenblatt) % has ranged from 184.23 to 2,189.79. According to the industry distribution chart, Cipher Pharmaceuticals ranks #3 out of 983 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Cipher Pharmaceuticals' ROC (Joel Greenblatt) % too high?
Cipher Pharmaceuticals' current ROC (Joel Greenblatt) % of 3,820.44% is 581% above median its 10-year median of 560.86. Over the past 10 years, this metric has ranged from a low of 184.23 to a high of 2,189.79. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Cipher Pharmaceuticals' value of 3,820.44% is 33237.2% above this industry median. Based on the distribution chart, Cipher Pharmaceuticals ranks #3 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #3 out of 983 companies for ROC (Joel Greenblatt) %. This places Cipher Pharmaceuticals in the top 0% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.46. Cipher Pharmaceuticals' value of 3,820.44% is 33237.2% above this benchmark. Historically, Cipher Pharmaceuticals' own ROC (Joel Greenblatt) % has ranged from 184.23 to 2,189.79 over the past decade. While the company's 10-year median is 560.86 vs. the industry median of 11.46, Cipher Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current ROC (Joel Greenblatt) % of 3,820.44% is 33237.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cipher Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current ROC (Joel Greenblatt) % is 3,820.44%, which is 581% above median its own 10-year median of 560.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.21, compared to a current price of $12.06 — trading 1.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 3,820.44%, which is 581% above median its 10-year median of 560.86 and 33237.2% above the Drug Manufacturers industry median of 11.46. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current ROC (Joel Greenblatt) % is 3,820.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?
Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued.
The current stock price of $12.06 is trading 1.2% below its estimated GF Value™ of $12.21.
GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.
Key valuation signals for CPHRF:
ROC (Joel Greenblatt) %: 3,820.44% (581% above median its 10-year median of 560.86)
GF Value™: $12.21 vs. price of $12.06 (1.2% below fair value)
Industry Position: 33237.2% above the Drug Manufacturers median (#3 of 983)
No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score
Get the complete analysis for CPHRF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHRF has been successfully added to your 
